The Food and Drug Administration’s (FDA) March 2015 approval of Zarxio, the first biosimilar product licensed under the Biologics Price Competition and Innovation Act of 2009 (BPIA) is expected to usher in a new wave of faster approvals, greater choice, and lower costs for the biologics market. Along with these exciting opportunities, however, come a host of new questions and uncertainties for manufacturers, health care providers, and payers for health care services. We explore these and other issues in a new article recently published in Bloomberg BNA Pharmaceutical Law and Industry Report, available here.